Appili Therapeutics Company Executives
| APLI Stock | CAD 0.03 0.01 14.29% |
Appili Therapeutics employs about 6 people. The company is managed by 6 executives with a total tenure of roughly 0 years, averaging almost 0.0 years of service per executive, having 1.0 employees per reported executive. Analysis of Appili Therapeutics' management performance can provide insight into the firm performance.
Appili |
Appili Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (2.4422) % which means that it has lost $2.4422 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (9.3872) %, meaning that it generated substantial loss on money invested by shareholders. Appili Therapeutics' management efficiency ratios could be used to measure how well Appili Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Appili Therapeutics' Return On Capital Employed is very stable compared to the past year. As of the 15th of March 2025, Return On Equity is likely to grow to 0.45, while Return On Tangible Assets are likely to drop (3.06). At this time, Appili Therapeutics' Non Current Assets Total are very stable compared to the past year. As of the 15th of March 2025, Other Current Assets is likely to grow to about 231.3 K, while Total Assets are likely to drop about 1.3 M.As of the 15th of March 2025, Common Stock Shares Outstanding is likely to grow to about 146.4 M, while Net Loss is likely to drop (8.7 M).
Appili Therapeutics Workforce Comparison
Appili Therapeutics is currently under evaluation in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 32.0. Appili Therapeutics adds roughly 0.0 in number of employees claiming only tiny portion of equities under Health Care industry.
Appili Therapeutics Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Appili Therapeutics Price Series Summation is a cross summation of Appili Therapeutics price series and its benchmark/peer.
Appili Therapeutics Notable Stakeholders
An Appili Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Appili Therapeutics often face trade-offs trying to please all of them. Appili Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Appili Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Arthur Baran | Director Development | Profile | |
| Carl Gelhaus | Director Research | Profile | |
| Cilla MBA | Pres CEO | Profile | |
| MS MD | Chief Officer | Profile | |
| Kenneth Howling | Acting Officer | Profile | |
| Gary Nabors | Chief Officer | Profile |
About Appili Therapeutics Management Performance
The success or failure of an entity such as Appili Therapeutics often depends on how effective the management is. Appili Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Appili management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Appili management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (2.92) | (3.06) | |
| Return On Capital Employed | 0.92 | 0.97 | |
| Return On Assets | (2.92) | (3.06) | |
| Return On Equity | 0.31 | 0.45 |
Appili Therapeutics Workforce Analysis
Traditionally, organizations such as Appili Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Appili Therapeutics within its industry.Appili Therapeutics Manpower Efficiency
Return on Appili Therapeutics Manpower
| Revenue Per Employee | 137.9K | |
| Revenue Per Executive | 137.9K | |
| Net Loss Per Employee | 630.2K | |
| Net Loss Per Executive | 630.2K |
Other Information on Investing in Appili Stock
Appili Therapeutics financial ratios help investors to determine whether Appili Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Appili with respect to the benefits of owning Appili Therapeutics security.